产品名称：**SU6656**
产品别名：**SU6656**

生物活性：

Description

SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

In Vitro

SU6656 decreases phosphorylation of Src family kinases (SFKs) in HNSCC cells[2].

In Vivo

SU6656 (2-4 mg/kg; i.p.; once) significantly decreases ischemic postconditioning (IPoCo) mediated increase in fall down time[5].

Animal Model:	Swiss albino male mice[5]
Dosage:	2, 4 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Significantly decreased IPoCo mediated increase in fall down time.

Solvent&Solubility

In Vitro:

DMSO : 18.5 mg/mL (**49.80 mM**; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6922 mL	13.4608 mL	26.9215 mL
	5 mM	0.5384 mL	2.6922 mL	5.3843 mL
	10 mM	0.2692 mL	1.3461 mL	2.6922 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

References

[1]. Blake RA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27.

[2]. Veracini L, et al. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2014 Dec 26.

[3]. Wu ML, et al. Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 2014 Mar 28;12:22.

[4]. Ondrusová L, et al. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7.

[5]. Kumar A, et al. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86.

[6]. Liu XF, et al. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther. 2014 Jan;13(1):82-9.